Natixis Advisors, LLC’s Regeneron Pharmaceuticals Position
Does Natixis Advisors, LLC own Regeneron Pharmaceuticals (REGN)? Yes — 125.7K shares worth $97M (+0.14% of its 13F portfolio) as of Q1 2026, up from 122.6K shares the prior filed quarter.
Position Value
$97M
Q1 2026
Shares
125.7K
% of Portfolio
+0.14%
Quarters Held
30
currently held
Position History REGN
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 125.7K | $97M | +0.14% |
| Q4 2025 | 122.6K | $95M | +0.13% |
| Q3 2025 | 120.1K | $68M | +0.10% |
| Q2 2025 | 113.0K | $59M | +0.09% |
| Q1 2025 | 116.2K | $74M | +0.14% |
| Q4 2024 | 109.9K | $78M | +0.15% |
| Q3 2024 | 117.0K | $123M | +0.24% |
| Q2 2024 | 116.7K | $123M | +0.27% |
| Q1 2024 | 114.0K | $110M | +0.25% |
| Q4 2023 | 110.4K | $97M | +0.26% |
| Q3 2023 | 111.0K | $91M | +0.28% |
| Q2 2023 | 111.1K | $80M | +0.25% |
| Q1 2023 | 112.0K | $92M | +0.32% |
| Q4 2022 | 107.4K | $77M | +0.29% |
| Q3 2022 | 134.9K | $93M | +0.39% |
| Q2 2022 | 135.2K | $80M | +0.35% |
| Q1 2022 | 175.9K | $123M | +0.47% |
| Q4 2021 | 181.3K | $114M | +0.44% |
| Q3 2021 | 252.9K | $153M | +0.63% |
| Q2 2021 | 137.1K | $77M | +0.36% |
| Q1 2021 | 138.3K | $65M | +0.34% |
| Q4 2020 | 143.4K | $69M | +0.40% |
| Q3 2020 | 186.5K | $104M | +0.66% |
| Q2 2020 | 194.5K | $121M | +0.81% |
| Q1 2020 | 209.3K | $102M | +0.83% |
| Q4 2019 | 208.7K | $78M | +0.55% |
| Q3 2019 | 210.4K | $58M | +0.46% |
| Q2 2019 | 206.9K | $65M | +0.53% |
| Q1 2019 | 206.4K | $85M | +0.74% |
| Q4 2018 | 199.1K | $74M | +0.73% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Natixis Advisors, LLC’s full portfolio or all institutional holders of REGN.